Pfizer.jpg” />

Merck and Pfizer have reported positive results from the Phase III VERTIS MET and VERTIS SITA clinical trials of ertugliflozin for patients with type 2 diabetes.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Ertugliflozin is an investigational oral SGLT-2 inhibitor currently being developed to improve glycemic control in adult patients.

Both trials are reported to have met the primary endpoint of a statistically significant decrease in A1C when added to metformin or initially administered with sitagliptin.

Pfizer global product development chief development officer James Rusnak said: “These results, combined with findings from other studies in the VERTIS programme, underscore the potential of ertugliflozin as an important therapeutic option for adults with type 2 diabetes to help improve their glycemic control.”

See Also:

The investigational multi-centre VERTIS MET trial assessed the safety and efficacy of 5mg and 15mg of ertugliflozin combined with metformin over 26 weeks in 621 patients whose disease is uncontrolled on metformin monotherapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial also showed a significant decrease in body weight, fasting plasma glucose (FPG), diastolic blood pressure (DBP) and systolic blood pressure (SBP).

"These results, combined with findings from other studies in the VERTIS programme, underscore the potential of ertugliflozin as an important therapeutic option for adults with type 2 diabetes to help improve their glycemic control."

In the 26-week, randomised, double-blind, investigational, multi-centre VERTIS SITA trial, the efficacy and safety of an initial combination therapy of both doses of ertugliflozin with 100mg of Merck’s DPP-4 inhibitor JANUVIA (sitagliptin) was evaluated in 291 subjects.

In comparison to placebo, the combination indicated a greater decrease in A1C, FPG, body weight and SBP.

The combination therapy in both the trials was reported to have met the secondary endpoint of A1C treatment goal of less than 7%.

The VERTIS clinical development programme of ertugliflozin includes nine Phase III trials in up to 12,600 adults with type 2 diabetes.

Image: Pfizer World Headquarters. Photo: courtesy of Coolcaesar.